Acceleration in the development of Theradiag’s In Vitro Diagnostics Business Unit with the development of the BioCLIA® 1 200

Croissy-Beaubourg and Montpellier, April 6, 2016 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, is announcing the launch of a next‑generation automated diagnostics system at the International Congress on Autoimmunity (ICA) in Leipzig (Germany) from April 6th  to 9th, 2016, an event bringing together international autoimmunity and theranostics specialists every two years.

The BioCLIA® 1 200 is a fourth-generation automated system that can harness the very latest chemiluminescence technology based on nanoparticles. This innovative new system can simultaneously manage several types of analysis (random access). Thanks to its new features and use of innovative technology, it can deliver results very rapidly – in less than an hour. In addition, this solution will offer a highly diversified immunoassay menu for autoimmunity, allergy and biotherapy monitoring purposes.

Under the cross-distribution agreement and partnership announced in November last year[1], the BioCLIA® 1 200 is being launched as a co-development with HOB Biotech, the leader in allergy and autoimmune in vitro diagnostics in China. HOB Biotech and Theradiag are co-developing a full range of autoimmunity, biotherapy monitoring and allergy reagents, which are scheduled for introduction gradually from 2017 onwards, on this new system. Theradiag is the exclusive distributor of this innovative new solution in Europe.

The initial results of evaluating autoimmunity products developed on the BioCLIA® 1 200 will be presented at a symposium during the ICA congress and in a poster: http://www.theradiag.com/fr/?p=6877.

“The launch of the BioCLIA® 1 200 is excellent news for Theradiag. The BioCLIA® 1 200 will re-energize our longstanding activities, especially in autoimmunity, our core area of expertise. With the future commercialization of autoimmune, allergy and theranostics diagnostics, Theradiag is accelerating the development of its In Vitro Diagnostics business unit as part of its drive for robust global growth. The co-development partnership with HOB Biotech will enable us to rapidly bring to market a solution offering our customers the best cost/benefit performance”, commented Michel Finance, Theradiag’s Chief Executive Officer.

Avec Bras avec LOGO

For more information about the BioCLIA® 1 200: www.theradiag.com/en/the-future-is-here

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

 

 

www.theradiag.com

TheradiagInvestor RelationsFabienne FrançoisCFO+33 1 64 62 10 12contact@theradiag.com

 

 

NewCapFinancial communications/ investor relationsValentine Brouchot/Pierre Laurent+33 1 44 71 94 94theradiag@newcap.eu

 

Alize RPPressCaroline Carmagnol/
Florence Portejoie
+33 1 44 54 36 64theradiag@alizerp.com